Delpor has declared that its microfabricated nanopore deviceused for therapeutic drug delivery has received patent from the United States Patent and Trademark Office on June 7, 2011.
The device makes use of Delpor’s in-house NANOPOR technology to enable a continuous zero-order discharge of small and large molecules for a number of months after performing subcutaneous implantation. Delpor has absolute rights to the patented technology and has quite a few patent-pending product candidates.
Delpor’s technology renders constant zero-order discharge of substances for a number of months by means of passive diffusion without an osmotic pump or any other mechanical components in the equipment. The rate of diffusion is controlled by a nanopore membrane which includes a set of channels with accurate geometry. The membrane also provides a zero-order rate of substance discharge.
President and CEO of Delpor, Tassos Nicolaou stated that this patent holds an important place in Delpor’s property portfolio. NANOPOR technology is a perfect tool for delivering therapeutic agents continuously without any mechanical components embedded inside the device used for this purpose. This allows better flexibility in formulation, eases the production process, and provides safety with osmotic systems.
Several therapeutic agents such as human growth hormone, interferon-alpha, and Glucagon-like peptide-1 (GLP-1) can be benefited from prolonged sustained delivery. Advantages of such delivery include increased efficiency, improved safety, adherence to medication, and convenience of patients during frequent subcutaneous injections.
Source: http://www.delpor.com